Overall, semaglutide remarkably lowers CV risk in T2DM, supporting its use for both glycemic control and CV risk reduction.[10] 1
It is administered as a once-weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm, with doses gradually increased over time to minimize gastrointestinal side effects
In 2023, major international societies endorsed a shift from the previous terminology, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), to MASLD and MASH [1]
Glutamate dehydrogenase v
Limit Spicy, Fatty, and Fried Foods : Spicy, fatty, and fried foods are common acid reflux triggers
Below are the most common, listed by generic name first with brand name in parentheses: Semaglutide (Wegovy, Ozempic) Tirzepatide (Zepbound, Mounjaro) Liraglutide (Saxenda) Orlistat (Xenical) Some of these peptides work differently in the body to aid in weight/fat loss